- Equillium (NASDAQ:EQ) has completed a pre-IND meeting with the FDA during which they discussed clinical development plans for itolizumab (EQ001) for the potential treatment of hospitalized COVID-19 patients.
- The company expects to finalize the protocol for a Phase 3 study and submit its IND application next month. The randomized, double-blind, placebo-controlled clinical trial should launch in Q4.
- It has begun applying to government agencies for funding support.
- Shares up 9% premarket on modest volume.